Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
|Articles|December 2, 2022
Infectious Disease Update: This Week's Top 5 Stories
Author(s)Nina Cosdon
With major updates in HIV, C difficile, hepatitis, yeast infections, and skin and soft tissue infections, this week's Infectious Disease Update has something for everyone.
Advertisement
Most weeks don't have major breakthroughs, studies, and approvals across the spectrum of infectious diseases. This week was an exception.
Watch and read all about the most significant news of the past week with Contagion's Infectious Disease Update.
On Wednesday, the FDA announced that Rebyota (RBX2660) is the first approved fecal microbiota product. The treatment is indicated to prevent recurrent C difficile infection in adults.
In episode 1 of this short video series, infectious diseases clinical pharmacy specialist Bruce M. Jones, PharmD, FIDSA, BCPS, the patients best suited for inpatient versus outpatient care for these infections.
A germline-targeting HIV vaccine candidate elicited broadly neutralizing antibodies in 97% of recipients.
Ibrexafungerp tablets (Brexafemme) were already FDA approved to treat vulvovaginal candidiasis (VVC) and have now received a second indication for the reduction of recurrent VVC (yeast infection).
Resistance to hepatitis C infection may be much greater than previously thought, according to new research by investigators at Trinity College Dublin that revealed associated biological factors.
Advertisement
Related to this article
In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
In the second episode of the series with Perry N. Halkitis, PhD, MS, MPH, he brings his personal experience to this topic and questions whether there should be a shift in who manages the primary care needs of these patients.
The federal agency gave the nod for the smallest once-daily single tablet regimen available for virologically suppressed adults with HIV, including those on complex regimens. The approval is based on the results of the 2 phase 3 ARTISTRY trials.
The federal agency gave the nod to dolutegravir (Tivicay PD), making it the first second-generation integrase inhibitor cleared for children with HIV weighing at least 2 kg, including eligible newborns.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.